Supernus Pharmaceuticals SUPN
NASDAQ SUPN
$43.08 -0.89 (-2.02%)
As of: Sep 30, 2026 · 3:59 PM EDT

Supernus Pharmaceuticals (SUPN) Capital Leases (2020)

Updated

Supernus Pharmaceuticals (SUPN) reported Capital Leases of $19.29 million for Q3 2020, up 4.9% from the prior quarter.

Analysis

Supernus Pharmaceuticals (SUPN) Capital Leases (2020) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn
10 Supernus Pharmaceuticals 2.56 Bn 1.21 Bn 185.39 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2020 19.29 Mn
Jun 30, 2020 18.38 Mn
API Access

Supernus Pharmaceuticals Capital Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=capital-leases&ticker=SUPN&period=max&api_key=YOUR_API_KEY